Nasopharyngeal carriage of streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy

Journal of Infectious Diseases

Volumn 201, Issue 10, 2010, Pages 1570-1579

  Dagan, Ron ^a   Givon Lavi, Noga ^a   Greenberg, David ^a   Fritzell, Bernard ^b   Siegrist, Claire Anne ^c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b Clinical Research and Development   (France)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; BACTERIAL IMMUNITY; BACTERIUM CARRIER; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GROUPS BY AGE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFANCY; INFANT; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX; OROPHARYNX; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; THROAT CULTURE; TREATMENT RESPONSE; VACCINATION; DRUG ADMINISTRATION; HETEROZYGOTE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY;

CARRIER STATE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; MALE; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE;

EID: 77951916861     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/652006     Document Type: Article

References (45)

1. Levine OS, Greenwood B. Opportunity and challenges for pneumococcal conjugate vaccines in low- and middle-income countries. In: Siber G, Klugman KP, Makela H, eds. Pneumococcal vaccines: the impact of conjugate vaccine. Washington, DC: ASM Press, 2008:405-418.
2. World Health Organization. Conclusions and recommendations from the Strategic Advisory Group of Experts to the Department of Immunizations, Vaccines, and Biologicals. Wkly Epidemiol Rec 2006; 81: 2-11. http://www.who.int/wer/en.
3. World Health Organization. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008; 42:373-384. http://www.who.int/ wer/en.
4. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7:597-606.
5. Borrow R, Stanford E, Waight P, et al. Serotype-specific immune unresponsiveness to pneumococcal conjugate vaccine following invasive pneumococcal disease. Infect Immun 2008; 76:5305-5309.
6. MacDonald NE, Halperin SA, Law BJ, Danzig LE, Granoff DM. Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine? JAMA 2000; 283:1826-1827.
7. Borrow R, Goldblatt D, Andrews N, Richmond P, Southern J, Miller E. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis 2001; 184:377-380. (Pubitemid 32662189)
8. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000; 181:761-764. (Pubitemid 30131856)
9. de Roux A, Schmole-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46:1015-1023.
10. Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008; 198: 1019-1027.
11. Blum MD, Dagan R, Mendelman PM, et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 2000; 18:2359-2367.
12. O'Brien KL, Dagan R, Makela H. Nasopharyngeal carriage. In: Siber G, Klugman KP, Makela H, eds. Pneumococcal vaccines: the impact of conjugate vaccine. ASM Press, Washington, DC, 2008:279-300.
13. Dominguez J, Blanco S, Rodrigo C, et al. Usefulness of urinary antigen detection by an immunochromatographic test for diagnosis of pneumococcal pneumonia in children. J Clin Microbiol 2003; 41:2161-2163.
14. Dowell SF, Garman RL, Liu G, Levine OS, Yang YH. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin Infect Dis 2001; 32:824-825.
15. Anjay MA, Anoop P. Diagnostic utility of rapid immunochromatographic urine antigen testing in suspected pneumococcal infections. Arch Dis Child 2008; 93:628-631.
16. Hamer DH, Egas J, Estrella B, MacLeod WB, Griffiths JK, Sempertegui F. Assessment of the Binax NOW Streptococcus pneumoniae urinary antigen test in children with nasopharyngeal pneumococcal carriage. Clin Infect Dis 2002; 34:1025-1028.
17. Central Bureau of Statistics. Statistical abstract of Israel. No.49. Jerusalem: Hemed Press, 1998.
18. Statistical yearbook of the Negev Bedouin. Beer-Sheva, Israel: BenGurion University of the Negev, 2004.
19. Central Bureau of Statistics. Statistical abstract of Israel. No.56. 2005. http://wwwl.cbs.gov.il/reader/shnaton/shnatone-new.htm?CYear = 2005&Vol = 56&CSubject = 30.
20. Levy A, Fraser D, Vardi H, Dagan R. Hospitalizations for infectious diseases in Jewish and Bedouin children in southern Israel. Eur J Epidemiol 1998; 14:179-186.
21. Givon-Lavi N, Greenberg D, Volkov T, Piglansky L, Dagan R. Inferior immunogenicity after primary immunization with CRM-conjugated 7valent pneumococcal vaccine administered at 2 doses (age 4 and 6 m) compared with 3 doses (age 2, 4 and 6 m). 25th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). ESPID, 2007. Abstract 105.
22. Barkai G, Greenberg D, Givon-Lavi N, Dreifuss E, Vardy D, Dagan R. Community prescribing and resistant Streptococcus pneumoniae. Emerg Infect Dis 2005;11:829-837.
23. Quataert SA, Kirch CS, Wiedl LJ, et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 1995; 2:590-597.
24. Concepcion NF, Frasch CE. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001;8: 266-272.
25. Quataert SA, Rittenhouse-Olson K, Kirch CS, et al. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f). Clin Diagn Lab Immunol 2004; 11:1064-1069.
26. Ekdahl K, Ahlinder I, Hansson HB, et al. Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae, experiences from the South Swedish Pneumococcal Intervention Project. Clin Infect Dis 1997; 25:1113-1117.
27. Gray BM, Converse GM 3rd, Dillon HC Jr. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 1980; 142:923-933.
28. Auranen K, Arjas E, Leino T, et al. Transmission of pneumococcal carriage in families: a latent Markov process model for binary longitudinal data. J Am Stat Assoc 2000; 95:1044-1053.
29. Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22:96-103.
30. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008; 47:1328-1338.
31. Orthopoulos GV, Theodoridou MC, Ladis VA, Tsousis DK, Spou- lou VI. The effect of 23-valent pneumococcal polysaccharide vaccine on immunological priming induced by 7-valent conjugate vaccine in asplenic subjects with beta-thalassemia. Vaccine 2009; 27:350-354.
32. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 1975; 56:1536-1547.
33. Leach A, Twumasi PA, Kumah S, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997; 175:200-204.
34. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178:870-874.
35. Norden CW, Michaels RH, Melish M. Effect of previous infection on antibody response of children to vaccination with capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1975; 132:69-74.
36. Pichichero ME. Immunological paralysis to pneumococcal polysaccharide in man. Lancet 1985; 2:468-471.
37. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009; 9:185-194.
38. Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S. Immaturity of the human splenic marginal zone in infancy: possible contribution to the deficient infant immune response. J Immunol 1989; 143:3200-3206.
39. Salt P, Banner C, Oh S, et al. Social mixing with other children during infancy enhances antibody response to a pneumococcal conjugate vaccine in early childhood. Clin Vaccine Immunol 2007; 14:593-599.
40. Kayhty H, Auranen K, Nohynek H, Dagan R, Makela H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines 2006; 5:651-668.
41. Jodar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003; 21:3265-3272.
42. World Health Organization. Recommendations for the production and control of pneumococcal vaccines. WHO Technical Report Series no. 927, annex 2. Geneva, Switzerland: World Health Organization, 2005.
43. Schuerman L, Prymula R, Henckaerts I, Poolman J. ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media. Vaccine 2007; 25:1962-1968.
44. Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Siber GR, Kohberger R. Serum serotype-specific pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis 2005; 192:367-376.
45. Millar EV, O'Brien KL, Bronsdon MA, et al. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1173-1179.